Spyre Therapeutics, Inc.
SYRE
$14.67
$0.543.82%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -208.02M | -214.90M | -185.98M | -364.23M | -338.79M |
| Total Depreciation and Amortization | -- | 0.00 | 0.00 | 416.00K | 964.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 55.14M | 80.85M | 65.06M | 253.36M | 243.12M |
| Change in Net Operating Assets | -4.53M | -17.20M | -35.50M | -369.00K | -5.21M |
| Cash from Operations | -157.41M | -151.25M | -156.42M | -110.82M | -99.91M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 0.00 | 475.00K | 475.00K |
| Cash Acquisitions | -- | 0.00 | 0.00 | 3.04M | 3.04M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -353.29M | -218.01M | -358.38M | -234.62M | -111.90M |
| Cash from Investing | -353.29M | -218.01M | -358.38M | -231.11M | -108.39M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 0.00 | 0.00 | -8.00K | -16.00K |
| Issuance of Common Stock | 243.89M | 102.80M | 89.83M | 89.33M | 84.96M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 169.21M | 253.76M | 253.76M | 463.76M | 294.56M |
| Repurchase of Preferred Stock | -355.00K | -355.00K | -12.77M | -12.64M | -12.64M |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.84M | -7.29M | -7.22M | -7.22M | -5.79M |
| Cash from Financing | 410.91M | 348.91M | 323.60M | 533.23M | 361.08M |
| Foreign Exchange rate Adjustments | -3.00K | 30.00K | -3.00K | 10.00K | 25.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -99.79M | -20.32M | -191.21M | 191.32M | 152.80M |